MedPath

Efficiency of Repetitive Transcranial Magnetic Stimulation (rTMS) Sessions After a Successful 3 Week-treatment in Fibromyalgia

Not Applicable
Completed
Conditions
Fibromyalgia
Interventions
Device: rTMS
Device: sham rTMS
Registration Number
NCT01942538
Lead Sponsor
Centre Hospitalier Esquirol
Brief Summary

Maintenance rTMS sessions after a successful 3week-rTMS treatment for subjects with fibromyalgia may maintain the clinical improvement.

Detailed Description

In a previous pilot study, a 3 week treatment with rTMS in fibromyalgia subjects induced a 40% improvement of pain feeling. Three months later, the pain level was still significantly reduced in comparison with the beginning of the treatment, but the clinical improvement was less than at the end of the treatment. We thus propose to realize real or sham rTMS sessions at 3 weeks interval during 6 months with subjects presenting a significant clinical improvement after a 3 week-rTMS or sham treatment to evaluate the response maintenance.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
78
Inclusion Criteria
  • presence of the criteria from the American College of Rheumatology (2010)for fibromyalgia diagnosis,
  • painful state for more than six months,
  • visual analogic scale evaluation > or = 5,
  • age between 18 and 70,
  • no modification in therapeutic treatment one month before and during the protocol
  • presence of actual or prior antalgic chronic treatment : pregabalin, duloxetine, milnacipran, gabapentin, venlafaxine, laroxyl, grade 1 or 2 antalgic
  • residence in Limoges or the periphery, or the ability to come to the hospital for the treatment
Exclusion Criteria
  • presence of non stabilized psychiatric comorbidity (personality trouble, addiction, suicide attempt, non controlled affective trouble),
  • active epilepsy,
  • previous cerebral traumatism, or cerebral surgery, intra-cranial hyper tension,
  • pacemaker, metallic pieces in the brain, cochlear ocular implant, or any metallic material contra indicating magnetic resonance imaging.
  • clozapine, bupropion, methadon, theophyllin, or other non chemical antalgic technic established during the previous month(kinesitherapy, relaxation, hypnosis...),
  • pregnancy, or administrative and judiciary protection, absence of health insurance.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
rTMSrTMSreal rTMS for 3 weeks but without clinical improvement
rTMS-shamrTMSsubjects receiving sham rTMS maintenance sessions after successful real rTMS treatment
rTMS-rTMSrTMSsubjects receiving real rTMS treatment and real rTMS maintenance sessions
rTMS-shamsham rTMSsubjects receiving sham rTMS maintenance sessions after successful real rTMS treatment
sham - shamsham rTMSsubjects receiving sham treatment and presenting a clinical improvement : they will be submitted to sham maintenance sessions
shamsham rTMSsham treatment for 3 weeks without clinical improvement
Primary Outcome Measures
NameTimeMethod
number of fibromyalgia subjects maintaining a clinical improvement with rTMS maintenance sessions during 6 months210 days

= number of fibromyalgia subjects maintaining a clinical improvement after a prior rTMS treatment (15 sessions in 3 weeks)and maintenance rTMS sessions administered at 42, 63, 84, 105, 126, 147, 168, 189, 210 days after inclusion in comparison with sham maintenance sessions.

clinical improvement is described as a 30% decrease from baseline in pain feeling (visual analogue scale) and a response ≥ 6 for the Patient's global impression of Change.

effect will be considered as maintained if criteria of clinical improvement present after 3 week rTMS treatment are conserved at 6 months rTMS or sham maintenance sessions.

Secondary Outcome Measures
NameTimeMethod
number of rTMS responders at 3week-rTMS treatment21 days

Trial Locations

Locations (2)

Centre Hospitalier Esquirol

🇫🇷

Limoges, France

Centre Hospitalier Universitaire

🇫🇷

Limoges, France

© Copyright 2025. All Rights Reserved by MedPath